Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

Status unconfirmed · Phase 1

Conditions studied: Solid Tumor, Relapsed Solid Neoplasm, Refractory Tumor

In brief

This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.

Key facts

Study ID

NCT04900519

Run by

Sorrento Therapeutics, Inc.

People needed

100

Starts

2021-11-24

Expected to finish

2025-03-01

Last updated by the study team

2023-01-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent
• Age ≥ 18 years
• ECOG Performance Status ≤ 2
• Histologically- or cytologically-confirmed solid tumor
• Patient has relapsed, is refractory to, or intolerant of standard of care therapy
• No available approved therapy that may provide clinical benefit (per Investigator)
• Measurable or evaluable disease by RECISTv1.14
• Life expectancy of > 12 weeks (per Investigator)
• Adequate laboratory parameters including:
• Absolute neutrophil count (ANC) ≥ 1500/mm3
• Platelets ≥ 100,000/mm3
• Hemoglobin ≥ 12 g/dL (in the absence of transfusion over the prior 2 weeks)
• AST/SGOT ≤ 2.5 x ULN (≤ 5 x ULN if known liver involvement)
• ALT/SGPT ≤ 2.5 x ULN (≤ 5 x ULN if known liver involvement)
• Total bilirubin ≤ 2.0 x ULN (unless diagnosis of Gilbert's syndrome in which case < 3.0 times ULN)
• Serum creatinine ≤ 2.0 x ULN or estimated GFR ≥ 45 mL/min (per Cockcroft- Gault equation)
• If residual treatment related toxicity from prior therapy:
• Treatment related toxicity resolved to ≤ Grade 1 (alopecia excepted), or
• Treatment related toxicity resolved to ≤ Grade 2 with prior approval of the Medical Monitor
• Willingness to comply with the study schedule and all study requirements
• [Females] Must be postmenopausal, surgically sterile, or agree to use adequate contraception (per Investigator) throughout the study and for a least 30 days following the last dose
• [Males] Must be surgically sterile or must agree to use adequate contraception (per Investigator) throughout the study and for at least 30 days following the last dose
• [Males] Willingness to refrain from donating sperm throughout the study and for at least 30 days following the last dose
• [Females] If of child-bearing potential, must have a negative serum pregnancy test

You may not qualify if…

• Participating in any other interventional clinical study
• Previous exposure to an anti-CD47 or SIRPα antibody
• ≤ 28 days (or 5 half-lives if shorter) between of systemic anti-tumor treatment (e.g., chemotherapy, endocrine therapy, immunotherapy, cellular therapy) and the 1st dose of STI-6643
• ≤ 28 days from prior irradiation (≤ 7 days from limited field irradiation for control of symptoms) and the 1st dose of STI-6643
• ≤ 28 days between major surgery (≤ 7 days from minor surgical procedures, no waiting period following central catheter placement)
• ≤ 7 days between administration of G-CSF, GM-CSF, erythropoietin, thrombopoietin or IL11 and the 1st dose of STI-6643
• ≤ 7 days between systemic immunosuppressive therapy in excess of 10 mg/day prednisone equivalent and the 1st dose of STI-6643 (topical or inhaled corticosteroids not restricted)
• ≤ 28 days between a live attenuated vaccine and the 1st dose of STI-6643
• Known central nervous system (CNS) involvement with tumor (e.g., metastases, meningeal carcinomatosis)
• Active second malignancy requiring ongoing systemic treatment
• History of primary immunodeficiency disorders
• History of active pulmonary tuberculosis
• History of COVID-19 symptoms unless COVID-19 test negative ≤ 72 hours of the 1st dose of STI-6643
• ≤ 12 weeks from an allogeneic hematopoietic stem cell transplant and C1D1 or active graft-versus-host disease (GvHD)
• Active infection (e.g., bacterial, viral, fungal) requiring systemic treatment ≤ 72 hours of the 1st dose of STI-6643
• Known HIV-positive with CD4+ cell counts < 350 cells/uL or a history of an AIDS defining opportunistic infection
• Known T-cell leukemia virus type 1 (HTLV1) infection, hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia
• Significant risk for HBV reactivation (defined as HbsAg positive, HbcAb positive or HBV DNA positive)
• Detectable HCV RNA
• Pregnant or breast feeding
• History of clinically significant cardiovascular abnormalities including:
• Congestive heart failure (NYHA classification ≥ 3) within 6 months of the 1st dose of STI-6643
• Unstable angina pectoris
• ≤ 6 months from myocardial infarction and the 1st dose of STI-6643
• Arrhythmias (other than atrial fibrillation) requiring ongoing treatment

Where it is running

• Sanford Health — Sioux Falls, South Dakota, United States (enrolling)
• Mary Crowley Cancer Research — Dallas, Texas, United States (enrolling)
• Virginia Cancer Specialists — Fairfax, Virginia, United States (enrolling)
• University of California, San Diego — San Diego, California, United States
• NEXT Oncology - Austin — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.